Læknablaðið - 15.03.2013, Side 15

RANNSÓKN
Heimildir
1. Bjömsson G. Prevalence and causes of blindness in
Iceland, with special reference to glaucoma simplex. Am J
Ophthalmol 1955; 39:202-8.
2. Bjömsson G. The Borgames Eye Study. Nordic Council
Arctic Medical Research Report 1980; 26: 34-9.
3. Jonasson F, Thordarson K. Prevalence of ocular disease
and blindness in a mral area in the eastem region of
Iceland during 1980 throughl984. Acta Ophthalmol Suppl
1987; 182: 40-3.
4. Organisation for Economic Co-operation and Develop-
ment. 2012; oecd.org/iceland/Briefing NotelCELAND
2012.pdf - nóvember 2012.
5. Hagstofa íslands 2012. hagstofa.is/Hagtolur/Mannfjoldi -
nóvember 2012.
6. Klein R, Klein BE, Linton KL, De Mets DL. The Beaver
Dam Eye Study: Visual acuity. Ophthalmology 1991; 98:
1310-5.
7. Attebo K, Mitchell P, Smith W. Visual acuity and the causes
of visual loss in Australia. The Blue Mountains Eye Study.
Ophthalmology 1996; 103: 357-64.
8. Buch H, Vinding T, La Cour M, Nielsen NV. The preva-
lence and causes of bilateral and unilateral blindness in an
elderly urban Danish population. The Copenhagen City
Eye Study. Acta Ophthalmol Scand 2001; 79:441-9.
9. Ivers RQ, Cumming RG, Mitchell P, Attebo K. Visual
impairment and falls in older adults: the Blue Mountains
Eye Study. J Am Geriatr Soc 1998; 46: 58-64.
10. Javitt JC, Zhouz, Wilke RJ. Association between vision loss
and higher medical care costs in Medicare beneficiaries.
Ophthalmology 2007; 144:238-45.
11. World Health Organization. Intemational statistical
classification of diseases and related health problems lOth
revision (ICD-10) Version for 2010. who.int/classifica-
tions/icd/en - nóvember 2012.
12. Gunnlaugsdottir E, Amarsson A, Jonasson F. Prevalence
and causes of visual impairment and blindness in
Icelanders aged 50 years and older: the Reykjavik Eye
Study. Acta Ophthalmol 2008; 86:778-85.
13. Gunnlaugsdottir E, Amarsson A, Jonasson F. Five-year
incidence of visual impairment and blindness in older
Icelanders: the Reykjavik Eye Study. Acta Ophthalmol
2010; 88; 358-66.
14. Jonasson F, Amarsson A, Sasaki H, Peto T, Sasaki K,
Bird AC. The prevalence of age-related maculopathy in
Iceland: Reykjavik Eye Study. Arch Ophthalmol 2003; 121:
379-85.
15. Jonasson F, Amarsson A, Peto T, Sasaki H, Sasaki K, Bird
AC. 5-year incidence of age-related maculopathy in the
Reykjavik Eye Study. Ophthalmology 2005; 112:132-8.
16. Jonasson F, Damji KF, Amarsson A, Sverrisson T, Wang
L, Sasaki H, et al. Prevalence of open-angle giaucoma in
Iceland: Reykjavik Eye Study. Eye (Lond) 2003; 17: 747-53.
17. Arnarsson Á, Jónasson F, Katoh N, Sasaki H, Jónsson
V, Kojima M, et al. Áhættuþættir skýmyndunar í berki
og kjama augasteins Reykvíkinga 50 ára og eldri.
Reykjavíkuraugnrannsóknin. Læknablaðið 2002; 88: 727-
31.
18. Katoh N, Jonasson F, Sasaki H, Kojima M, Ono M,
Takahashi N, et al. Reykjavik Eye Study Group. Cortical
lens opacification in Iceland. Risk factor analysis—
Reykjavik Eye Study. Acta Ophthalmol Scand 2001; 79:
154-9.
19. Gudmundsdottir E, Jonasson F, Jonsson V, Stefánsson E,
Sasaki H, Sasaki K. "With the rule" astigmatism is not
the mle in the elderly. Reykjavik Eye Study: a population
based study of refraction and visual acuity in citizens of
Reykjavik 50 years and older. Iceland-Japan Co-Working
Study Groups. Acta Ophthalmol Scand 2000; 78: 642-6.
20. Gudmundsdottir E, Amarsson A, Jonasson F. Five-year
refractive changes in an adult population: Reykjavik Eye
Study. Ophthalmology 2005; 112:672-7.
21. Olsen T, Amarsson A, Sasaki H, Sasaki K, Jonasson F.
On the ocular refractive components: the Reykjavik
Eye Study. Acta Ophthalmol Scand 2007; 85: 361-6.
22. Klein R, Wang Q, Klein BE, Moss SE, Meuer SM. The
relationship of age-related maculopathy, cataract, and
glaucoma to visual acuity. Invest Ophthalmol Vis Sci 1995;
36:182-91.
23. Munoz B, West SK, Rubin GS, Schein OD, Quigley HA,
Bressler SB, et al. Causes of blindness and visual impair-
ment in a population of older Americans: The Salisbury
Eye Evaluation Study. Arch Ophthalmol 2000; 118:819-25.
24. Wang JJ, Foran S, Mitchell P. Age-specific prevalence and
causes of bilateral and unilateral visual impairment in
older Australians: the Blue Mountains Eye Study. Clin
Experiment Ophthalmol 2000; 28:268-73.
25. Foran S, Mitchell P, Wang JJ. Five-year change in visual
acuity and incidence of visual impairment: the Blue
Mountains Eye Study. Ophthalmology 2003; 110: 41-50.
26. Sverrisson T. Visual impairment in patients with chronic
open angle glaucoma. Acta Ophthalmol 1990: 68 (suppl
195): 71-3.
27. Umferðarstofa. Reglugerð um ökuskírteini nr. 830/2011.
III. Viðauki, liður 6.1. Lágmarkskröfur um andlega og
líkamlega hæfni til að stjóma vélknúnu ökutæki.
28. Geirsdottir A, Jonsson O, Thorisdottir S, Helgadottir G,
Jonasson F, Stefansson E, et al. Population-based incidence
of exudative age-related degeneration and ranibizumab
treatment load. Br J Ophthalmol 2012; 96:444-7.
29. Age-related eye disease study research group.
Randomized placebo controlled clinical trial of high dose
supplementation with vitamin C, E, betacarotin and zinc
for age related macular degeneration and vision loss.
AREDs Report no. 8. Arch Ophthalmol 2001; 119:1417-36.
30. Stefánsson E, Bek T, Porta M, Larsen N, Kristinsson
JK, Agardh E. Screening and prevention of diabetic
blindness. Acta Ophthalmol Scand 2000; 78: 374-85.
ENGLISH SUMMARY
Visual impairment and blindness in lcelanders aged 50 years and older - The Reykjavík Eye Study
Gunnlaugsdóttir E, Arnarsson AM, Jónasson F
Introduction: The purpose of this study was to examine the cause-
specific prevalence and 5-year incidence of visual impairment and
blindness among middle-aged and older citizens of Reykjavík.
Material and methods: A random sample of 1045 persons aged 50
years or older underwent a detailed eye examination in 1996 and 846
of the survivors participated in a follow-up examination in 2001. Visual
impairment was defined according to World Health Organization defini-
tions as a best-corrected visual acuity of <6/18 but no worse than 3/60,
or visual field of 25° and <10° around a fixation point in the better eye.
Best-corrected visual acuity of <3/60 in the better eye was defined as
blindness. The causes of visual impairment or blindness were determ-
ined for all eyes with visual loss.
Results: The prevalence of bilateral visual impairment and blindness
was 1.0% (95% Cl 0.4-1.6) and 0.6% (95% Cl 0.1-1.0), respectively and
the 5-year incidence was 1.1 % (95% Cl 0.4-1.8) and 0.4% (95% Cl 0.0-
0.8), respectively. The prevalence of visual impairment among 60-69
year old participants was 0.6%, but among those aged 80 years or older
the prevalence was 7.9%. The major cause of bilateral visual impairment
and blindness both at baseline and follow-up was age-related macular
degeneration. Cataract accounted for less severe visual loss. The two
most common causes of unilateral visual impairment at baseline were
amblyopia and cataract. Cataract was the main cause of unilateral visual
impairment at 5-year follow-up.
Conclusion: Prevalence and 5-year incidence of both uni- and bilateral
visual impairment and blindness increases with age. Age-related
macular degeneration was the leading cause of severe visual loss in this
population of middle-aged and older lcelanders.
Key words: Age-related macular degeneration, blindness, cataract, incidence, prevalence, visualimpairment.
Correspondence: Elín Gunnlaugsdóttir elingun@gmail.com
'Department of Ophthalmology, Landspítali University Hospital, Reykjavík, lceland, 2Faculty of Medicine, University of lceland, Reykjavík,3Neuroscience research, University of Akur-
eyri, Akureyri.
LÆKNAblaðið 2013/99 127